Mannitol and other diuretics in severe neurotrauma

Area of Science:

• Neurology
• Nephrology
• Critical Care Medicine

Background:

• Elevated intracranial pressure (ICP) is a critical complication following brain injury.
• Mannitol has emerged as a primary therapeutic agent for managing increased ICP.
• Understanding optimal administration and monitoring is crucial for patient safety.

Purpose of the Study:

• To review the established role of mannitol in controlling elevated ICP.
• To outline the recommended dosage, administration protocols, and clinical indications for mannitol use.
• To highlight safety considerations and monitoring parameters for mannitol therapy.

Main Methods:

• Review of existing literature on mannitol's efficacy and safety in managing elevated ICP.
• Analysis of recommended dosing (0.25–1.0 g/kg) and administration as a bolus infusion (10–30 mins).
• Discussion of clinical scenarios including suspected high ICP, pre-operative use, and ICU management.

Main Results:

• Mannitol is the first-choice diuretic for controlling raised ICP post-brain injury.
• Bolus intravenous infusion is more effective and safer than continuous infusion.
• Safe use in hypovolemic patients with head injury is possible with simultaneous fluid resuscitation.
• Monitoring serum osmolality (< 320 mOsm) is essential to prevent renal failure.

Conclusions:

• Mannitol is a highly effective agent for reducing elevated intracranial pressure.
• Optimal administration involves bolus IV infusion with careful monitoring of serum osmolality and renal function.
• Its use is indicated in various clinical settings, including emergency, pre-operative, and intensive care.